New weekly shot aims to tackle high blood pressure and obesity together
NCT ID NCT07469800
First seen Apr 04, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This Phase 3 trial tests a drug called IBI362 in people with mild to moderate high blood pressure who are also overweight or obese. Participants receive weekly injections of either the drug or a placebo for 48 weeks. The main goal is to see if IBI362 lowers blood pressure more than placebo at 16 weeks, with additional checks on weight loss and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI362 (a drug injected under the skin once a week)
What this could lead to
If it works, this could offer a new treatment option that lowers both blood pressure and body weight in people with hypertension and overweight or obesity.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results may not apply to everyone with hypertension.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.